Satisfaction and quality of life of allergic patients following sublingual five-grass pollen tablet immunotherapy in Spain
Open Access
- 29 November 2017
- journal article
- Published by BioExcel in Drugs in Context
- Vol. 6, 1-14
Abstract
Five-grass pollen tablet is an effective and well-tolerated therapy for patients with allergic rhinoconjunctivitis (ARC). This trial sought to determine the satisfaction and health-related quality of life (HRQoL) of patients undergoing this treatment. This was a cross-sectional, multicentre, observational, naturalistic study, following a discontinuous pre- and co-seasonal five-grass pollen regimen over two seasons in Spain (2012, 2013). The HRQoL of the patients was measured with the specific Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) for adults, adolescent (AdolRQLQ), or paediatric (PRQLQ) patients. Treatment satisfaction was assessed by the Satisfaction Scale for Patients Receiving Allergen Immunotherapy (ESPIA) questionnaire. Patients/investigators were surveyed on beliefs and attitudes towards the five-grass pollen tablet. ARC evolution according to allergic rhinitis and its impact on asthma (ARIA) criteria and treatment adherence were evaluated. Among the 591 ARC patients included, the mean (SD) HRQoL scores were 1.40 (1.1) in adults, 1.33 (1.1) in adolescents, and 1.15 (1.1) in children, indicating low levels of impairment (scale 0-6). ESPIA answers showed high levels of satisfaction, with an average score of 69.2 (scale 0-100). According to ARIA criteria, 88.2% of patients reported improvement of ARC. Moreover, this was accompanied by a reduced use of symptomatic medication. Adherence to treatment was estimated at 96.8%. In general, both patients and specialists exhibited a positive attitude towards five-grass pollen tablet treatment. ARC patients treated with five-grass pollen tablet showed favourable levels of HRQoL and treatment satisfaction, with concomitant improvements in ARC and symptomatic medication use, which translated into high levels of treatment adherence and a positive attitude towards five-grass pollen tablet.Keywords
This publication has 35 references indexed in Scilit:
- An observational, real‐life safety study of a 5‐grass pollen sublingual tablet in children and adolescentsPediatric Allergy and Immunology, 2014
- 300IR 5-Grass Pollen Sublingual Tablet Offers Relief from Nasal Symptoms in Patients with Allergic RhinitisAmerican Journal of Rhinology & Allergy, 2014
- 5-grass pollen tablets achieve disease control in patients with seasonal allergic rhinitis unresponsive to drugs: a real-life studyJournal of Asthma and Allergy, 2013
- Allergic Rhinitis and Its Impact on Work Productivity in Primary Care Practice and a Comparison with Other Common Diseases: The Cross-sectional Study to Evaluate Work Productivity in Allergic Rhinitis Compared with Other Common Diseases (CAPRI) StudyAmerican Journal of Rhinology & Allergy, 2012
- Medical Management and Sublingual Immunotherapy Practices in Patients with House Dust Mite-Induced Respiratory Allergy: A Retrospective, Observational StudyInternational Journal of Immunopathology and Pharmacology, 2012
- Molecular variability of group 1 and 5 grass pollen allergens between Pooideae species: implications for immunotherapyClinical & Experimental Allergy, 2010
- Sub‐lingual Immunotherapy: World Allergy Organization Position Paper 2009Allergy, 2009
- Overview of comorbid associations of allergic rhinitisJournal of Allergy and Clinical Immunology, 1997
- Grass pollen immunotherapy: efficacy and safety during a 4‐year follow‐up studyAllergy, 1995
- Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitisClinical & Experimental Allergy, 1991